2026 Dyslipidemia Guideline: Target-Driven Therapy and the End of the Nonstatin Stepladder
🔓 Free Teaser Reference Card Cardiology
Aug 2, 2026 · Published in: PharmD Signal Reference Card
How the 2026 ACC/AHA guideline changes lipid clinic workflows with absolute LDL-C targets, non-sequential nonstatin selection, and universal Lp(a) testing.
In-Hospital Dapagliflozin Misses Primary Endpoint but Mortality Signal Persists
🔓 Free Teaser Analysis Cardiology Confirmatory Grade: Moderate
Berg DD, Patel SM, Haller PM, et al.
Jan 1, 2025 · Published in: Circulation
The largest, most rigorous trial of in-hospital sodium-glucose cotransporter-2 inhibitor initiation was formally neutral, but pooled trial data continue to support early inpatient start for hospitalized heart failure patients.
CYP2C19-Guided DAPT De-Escalation: Cost Savings, No Clinical Signal
Analysis Cardiology Hypothesis-generating Grade: Low
Turaev FK, Abdullaev SP, Matrenin KI, et al.
Sep 26, 2026 · Published in: Journal of Clinical Medicine
Genotype-guided antiplatelet therapy reduces costs without altering clinical outcomes.
Ultrashort DAPT Cuts Bleeding in ACS Without Raising Overall Ischemia
★ Editor's Pick Analysis Cardiology Confirmatory Grade: Moderate
Hendrianus H, Gorog DA, Tantry US, et al.
Sep 14, 2026 · Published in: JACC. Cardiovascular Interventions
Ultrashort DAPT reduces bleeding without raising overall ischemic events in PCI-treated ACS patients.
OAC Monotherapy Cuts Bleeding Without Ischemic Penalty in CCS
Analysis Anticoagulation / Hematology Confirmatory Grade: Moderate
Liang S, Chen X, Wang D, et al.
Aug 20, 2026 · Published in: Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Also in Cardiology
OAC monotherapy reduces bleeding in CCS without adding ischemic risk.
2026 Dyslipidemia Guideline Adds 25 Million Statin Candidates
Analysis Cardiology Confirmatory Grade: Moderate
Sayed A, Peterson ED, Navar AM
Aug 12, 2026 · Published in: Journal of the American College of Cardiology
2026 guidelines expand statin eligibility for millions of adults.
Tirzepatide Beats Dulaglutide on Cardiorenal Outcomes in Real-World HFpEF
★ Editor's Pick Analysis Cardiology Hypothesis-generating Grade: Low
Khalil I, Hossain MI, Akter MM, et al.
Aug 10, 2026 · Published in: Clinical Cardiology
Also in Endocrinology / Diabetes / Obesity
Tirzepatide outperforms dulaglutide in cardiorenal protection for HFpEF.
Anticoagulation Bests Antiplatelets After Mitral TEER in AF
Analysis Anticoagulation / Hematology Hypothesis-generating Grade: Very Low
Zhu F, Yu Z, He Z
Aug 5, 2026 · Published in: Frontiers in Cardiovascular Medicine
Also in Cardiology
OAC strategies may reduce bleeding risk post-TMVR.
Early In-Hospital ARNI After MI: Promising but PARADISE-MI Anchors Caution
Analysis Cardiology Hypothesis-generating Grade: Low
Nguyen Q, Tran TTQ, Liao CT, et al.
Aug 5, 2026 · Published in: Frontiers in Cardiovascular Medicine
Early ARNI therapy post-AMI cuts cardiovascular events by 42%.
MR Overactivation Reframes HFpEF as a Treatable Neurohormonal Continuum
Analysis Cardiology Confirmatory Grade: Moderate
Kobayashi M, Pitt B, Zannad F
Aug 3, 2026 · Published in: European Heart Journal
Targeting mineralocorticoid receptor overactivation shows promise in HFpEF management.
2025 Hypertension Thresholds Could Avert 200,000 US Deaths
Analysis Cardiology Confirmatory Grade: Low
Al-Jarshawi M, Bangalore S, Wijeysundera HC, et al.
Jul 29, 2026 · Published in: Journal of the American Heart Association
New guidelines could prevent over 200,000 deaths in a decade.
No Advantage for Rhythm Control in Post-Cardiac Surgery AF
Analysis Cardiology Confirmatory Grade: Very Low
Dairi MS, Tarabzoni M, Tarola C, et al.
Jul 29, 2026 · Published in: Frontiers in Cardiovascular Medicine
Also in Perioperative / Anesthesia
Rhythm control offers no clear advantage over rate control post-cardiac surgery.
ACE Inhibitors Beat ARBs for Cardiovascular Mortality in High-Risk Patients
Analysis Cardiology Confirmatory Grade: Moderate
Masi S, Savarese G, Orsini N, et al.
Jul 29, 2026 · Published in: European Heart Journal Open
ACE inhibitors outperform ARBs in reducing heart risks.
Acoramidis Slows Health Status Decline in ATTR-CM
Analysis Cardiology Confirmatory Grade: High
Sherrod CF 4th, Fontana M, Gillmore JD, et al.
Jul 29, 2026 · Published in: JAMA Cardiology
Acoramidis significantly improves quality of life for ATTR-CM patients.
Bayesian Synthesis Finds LAAO Fails Stroke Non-Inferiority Versus Anticoagulation
Analysis Anticoagulation / Hematology Confirmatory Grade: Moderate
Athmakuri KS, Nandyal SR, Pamreddy HR, et al.
Jul 22, 2026 · Published in: Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
Also in Cardiology
LAAO reduces bleeding but not strokes compared to anticoagulation.